Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145938 | 1.00 | TSHR (0.49) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL23779171 | 1.00 | TSHR (0.49) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL23779169 | 0.98 | TSHR (0.47) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL23779166 | 0.98 | TSHR (0.47) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL5319908 | 0.90 | TSHR (0.50) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL6185629 | 0.90 | TSHR (0.50) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL24322606 | 0.90 | TSHR (0.50) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL493454 | 0.89 | CHRNB2 (0.62) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL2591580 | 0.87 | CHRNB2 (0.60) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| Ammonia Solution, Strong SCHEMBL1764234 | 0.87 | CHRNB2 (0.60) | TSHRSMN1; SMN2CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-112955215-B | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-112955214-B | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3873599-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-2496230-A1 | IRE-1 ALPHA INHIBITORS | MannKind Corporation (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011056744-A1 | IRE-1 α INHIBITORS | MANNKIND CORPORATION (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056744-A1 | IRE-1 α INHIBITORS | MANNKIND CORPORATION (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7547722-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| US-7547722-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-7268158-B2 | 6H-THIENO [2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (GnRH) | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7268158-B2 | 6H-THIENO [2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (GnRH) | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | GNRHR, PRLHR, GHRHR | TSHR 20/4885SMN1; SMN2 4706/4885CHRNB2 1740/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | TSHR 704/4885SMN1; SMN2 3676/4885CHRNB2 4864/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | TSHR 4751/4885SMN1; SMN2 3096/4885CHRNB2 3816/4885 |
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | ARSA, SULT1A1, SULT2A1 | TSHR 1733/4885SMN1; SMN2 1024/4885CHRNB2 3287/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TSHR 4751/4885SMN1; SMN2 3096/4885CHRNB2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.